JP2013536855A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536855A5 JP2013536855A5 JP2013527250A JP2013527250A JP2013536855A5 JP 2013536855 A5 JP2013536855 A5 JP 2013536855A5 JP 2013527250 A JP2013527250 A JP 2013527250A JP 2013527250 A JP2013527250 A JP 2013527250A JP 2013536855 A5 JP2013536855 A5 JP 2013536855A5
- Authority
- JP
- Japan
- Prior art keywords
- rarγ
- use according
- agonist
- muscle tissue
- myopathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 claims 18
- 108091008760 retinoic acid receptors γ Proteins 0.000 claims 18
- 239000000556 agonist Substances 0.000 claims 14
- 210000003205 muscle Anatomy 0.000 claims 11
- 208000021642 Muscular disease Diseases 0.000 claims 5
- 201000009623 Myopathy Diseases 0.000 claims 5
- 206010028289 Muscle atrophy Diseases 0.000 claims 4
- 201000000585 muscular atrophy Diseases 0.000 claims 4
- AANFHDFOMFRLLR-UHFFFAOYSA-N 3-fluoro-4-[[2-hydroxy-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)acetyl]amino]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C(O)C(=O)NC1=CC=C(C(O)=O)C=C1F AANFHDFOMFRLLR-UHFFFAOYSA-N 0.000 claims 2
- VCQGNUWOMLYNNG-UHFFFAOYSA-N 4-[7-(1-adamantyl)-6-hydroxynaphthalen-2-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=C(O)C(=C2)C34CC5CC(CC(C5)C3)C4)C2=C1 VCQGNUWOMLYNNG-UHFFFAOYSA-N 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 2
- LDGIHZJOIQSHPB-UHFFFAOYSA-N CD437 Chemical compound C1C(C2)CC(C3)CC2CC13C1=CC(C2=CC3=CC=C(C=C3C=C2)C(=O)O)=CC=C1O LDGIHZJOIQSHPB-UHFFFAOYSA-N 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 claims 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical group C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000020763 muscle atrophy Effects 0.000 claims 2
- AANFHDFOMFRLLR-LJQANCHMSA-N r-3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acid Chemical compound O=C([C@H](O)C=1C=C2C(C)(C)CCC(C2=CC=1)(C)C)NC1=CC=C(C(O)=O)C=C1F AANFHDFOMFRLLR-LJQANCHMSA-N 0.000 claims 2
- 108091008726 retinoic acid receptors α Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000000451 tissue damage Effects 0.000 claims 2
- 231100000827 tissue damage Toxicity 0.000 claims 2
- VUXBMFIYPGMZTI-UHFFFAOYSA-N 6-[3-(1-adamantyl)-4-prop-2-ynoxyphenyl]naphthalene-2-carboxylic acid Chemical compound C1C(C2)CC(C3)CC2CC13C1=CC(C2=CC3=CC=C(C=C3C=C2)C(=O)O)=CC=C1OCC#C VUXBMFIYPGMZTI-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- YTFHCXIPDIHOIA-DHZHZOJOSA-N Palovarotene Chemical compound C1=CC=NN1CC=1C=C2C(C)(C)CCC(C)(C)C2=CC=1\C=C\C1=CC=C(C(O)=O)C=C1 YTFHCXIPDIHOIA-DHZHZOJOSA-N 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37899610P | 2010-09-01 | 2010-09-01 | |
| US61/378,996 | 2010-09-01 | ||
| PCT/US2011/049905 WO2012030919A2 (en) | 2010-09-01 | 2011-08-31 | Composition and method for muscle repair and regeneration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013536855A JP2013536855A (ja) | 2013-09-26 |
| JP2013536855A5 true JP2013536855A5 (enExample) | 2014-10-16 |
| JP5986570B2 JP5986570B2 (ja) | 2016-09-06 |
Family
ID=45773490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013527250A Active JP5986570B2 (ja) | 2010-09-01 | 2011-08-31 | 筋修復および再生のための組成物および方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US9789074B2 (enExample) |
| EP (3) | EP4066826B1 (enExample) |
| JP (1) | JP5986570B2 (enExample) |
| CN (2) | CN103200937B (enExample) |
| AU (1) | AU2011296080B2 (enExample) |
| BR (1) | BR112013004685B1 (enExample) |
| CA (1) | CA2809374C (enExample) |
| CL (1) | CL2013000580A1 (enExample) |
| CO (1) | CO6680694A2 (enExample) |
| DK (2) | DK2613776T3 (enExample) |
| EA (1) | EA026251B1 (enExample) |
| ES (3) | ES2823234T3 (enExample) |
| HU (2) | HUE059024T2 (enExample) |
| IL (1) | IL224973B (enExample) |
| MX (2) | MX361414B (enExample) |
| NZ (1) | NZ607547A (enExample) |
| PL (2) | PL3721880T3 (enExample) |
| PT (1) | PT2613776T (enExample) |
| WO (1) | WO2012030919A2 (enExample) |
| ZA (1) | ZA201301536B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103200937B (zh) | 2010-09-01 | 2020-07-03 | 托马斯杰弗逊大学 | 用于肌肉修复和再生的组合物和方法 |
| US11026952B2 (en) | 2011-06-16 | 2021-06-08 | President And Fellows Of Harvard College | Small molecules for mouse satellite cell proliferation |
| US11963964B2 (en) | 2011-06-16 | 2024-04-23 | President And Fellows Of Harvard College | Small molecules for mouse satellite cell proliferation |
| US9782417B2 (en) | 2011-06-16 | 2017-10-10 | Presidents And Fellows Of Harvard College | Methods of increasing satellite cell proliferation with kinase inhibitors |
| SG11201503612QA (en) | 2012-11-08 | 2015-06-29 | Univ Yamaguchi | Therapeutic agent for keratoconjunctive disorders |
| EP2943564A4 (en) | 2013-01-09 | 2016-10-26 | Int Stem Cell Corp | SMALL MOLECULES TO PROMOTE SKIN RECREATION |
| KR102303316B1 (ko) | 2013-05-22 | 2021-09-23 | 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 | 망막 맥락막 장해의 억제제 |
| EP3152190B1 (en) | 2014-06-04 | 2024-07-31 | Haro Pharmaceutical Inc. | 18-20 member bi-polycyclic compounds |
| US9784665B1 (en) * | 2014-12-29 | 2017-10-10 | Flagship Biosciences, Inc. | Methods for quantitative assessment of muscle fibers in muscular dystrophy |
| RU2724525C2 (ru) | 2015-05-06 | 2020-06-23 | Юниверсити Оф Саутерн Калифорния | Способ лечения повышенных уровней инсулина или глюкозы с использованием гипокалорийного или бескалорийного рациона или рациона, имитирующего воздержание от пищи |
| EP3091084A1 (en) | 2015-05-08 | 2016-11-09 | Université Catholique De Louvain | Methods for assessing the purity of a mesenchymal stem cells preparation |
| CN109069516A (zh) * | 2016-02-01 | 2018-12-21 | 哈佛学院校长同事会 | 用于小鼠卫星细胞增殖的小分子 |
| CN120204216A (zh) | 2016-06-08 | 2025-06-27 | 同理制药公司 | 用于治疗异位骨化的方法 |
| KR20190100187A (ko) | 2016-11-16 | 2019-08-28 | 클레멘티아 파마슈티컬즈, 인크. | 다중 골연골종(mo)을 치료하는 방법 |
| CA3019069A1 (en) * | 2018-04-02 | 2019-10-02 | Hubit Genomix, Inc. | Prophylactic and/or therapeutic drug for diabetic nephropathy |
| US11135236B2 (en) * | 2018-04-10 | 2021-10-05 | Northwestern University | Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity |
| GB201907647D0 (en) * | 2019-05-30 | 2019-07-17 | King S College London | Therapeutic methods |
| FR3112684B1 (fr) * | 2020-07-24 | 2022-08-12 | Univ Grenoble Alpes | Composés pour le traitement de l’hémophilie |
| CN116891497B (zh) * | 2022-04-02 | 2025-12-16 | 上海旭成医药科技有限公司 | 视黄酸受体激动剂、其制备方法、中间体、药物组合物和应用 |
| WO2023241715A1 (zh) * | 2022-06-16 | 2023-12-21 | 中国科学院动物研究所 | 视黄酸受体激活剂及其组合在哺乳动物再生修复中的应用 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| JPS60500864A (ja) | 1983-02-04 | 1985-06-06 | ワドリ、テクナラジズ、インコーパレイティド | 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ |
| GB2148299B (en) | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
| JPS6253981A (ja) | 1985-09-02 | 1987-03-09 | Koichi Shiyudo | 新規安息香酸誘導体 |
| AU618590B2 (en) | 1988-04-11 | 1992-01-02 | Allergan, Inc. | Tetralin esters of phenols or benzoic acids having retinoid like activity |
| CA2129773C (en) | 1993-09-02 | 2007-05-01 | Michael Klaus | Aromatic carboxylic acid derivatives |
| US5408002A (en) | 1993-09-09 | 1995-04-18 | Minnesota Mining And Manufacturing Company | Azlactone-functional polymer blends, articles produced therefrom and methods for preparing both |
| US5498795A (en) | 1994-12-29 | 1996-03-12 | Allergan, Inc. | Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5807900A (en) | 1995-03-31 | 1998-09-15 | Hoffmann-La Roche, Inc. | Method for identifying compounds having increased activity for the repair of skin photodamage |
| US5624957A (en) | 1995-06-06 | 1997-04-29 | Bristol-Myers Squibb Company | Rary-specific retinobenzoic acid derivatives |
| FR2739557B1 (fr) * | 1995-10-09 | 1997-11-14 | Cird Galderma | Utilisation d'un ligand agoniste specifique rar-gamma |
| FR2739777B1 (fr) * | 1995-10-11 | 1997-11-14 | Cird Galderma | Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose |
| US5726191A (en) | 1995-11-16 | 1998-03-10 | Hoffmann-La Roche Inc. | Aromatic carboxylic acid esters |
| US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| FR2747041B1 (fr) | 1996-04-05 | 1998-05-22 | Cird Galderma | Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies |
| US5945577A (en) | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
| US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| EP0989855A4 (en) * | 1997-05-13 | 2002-06-12 | Osiris Therapeutics Inc | REGENERATION OF CARTILAGE IN OSTEOARTHRITIS BY MEANS OF HUMAN MESENCHYMAL STEM CELLS |
| US7514074B2 (en) * | 1997-07-14 | 2009-04-07 | Osiris Therapeutics, Inc. | Cardiac muscle regeneration using mesenchymal stem cells |
| DE69936720T2 (de) | 1998-05-29 | 2008-04-30 | Osiris Therapeutics, Inc. | Menschliche cd45+ und/oder fibroblasten+ mesenchymale stammzellen |
| EP1115395A1 (en) | 1998-09-24 | 2001-07-18 | Bristol-Myers Squibb Company | ACTIVE ENANTIOMER OF RARgamma-SPECIFIC AGONIST |
| JO2178B1 (en) | 1999-10-19 | 2003-04-23 | اف . هوفمان لاروش ايه جي | Treatment of invasive diseases, using selected anti-PAR materials |
| US20030114482A1 (en) | 1999-12-15 | 2003-06-19 | Maurizio Pacifici | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies |
| US6313168B1 (en) | 1999-12-15 | 2001-11-06 | Allergan Sales, Inc. | Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
| JP2003526677A (ja) | 2000-03-14 | 2003-09-09 | ザ・ユニバーシテイ・オブ・ウエスタン・オンタリオ | 骨形成に影響を与える組成物および方法 |
| ATE328067T1 (de) | 2000-04-28 | 2006-06-15 | Childrens Medical Center | Isolierung von mesenchymalen stammzellen und deren verwendung |
| CN1321101C (zh) | 2000-10-02 | 2007-06-13 | 霍夫曼-拉罗奇有限公司 | 用于治疗肺气肿的新的类维生素a类化合物 |
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| MXPA04002305A (es) | 2001-09-18 | 2004-06-29 | Hoffmann La Roche | Agonistas ii de retinoides de urea sustituida. |
| BR0212583A (pt) | 2001-09-18 | 2004-10-13 | Hoffmann La Roche | Agonistas i para retinóides de alquil uréia |
| AUPR892501A0 (en) * | 2001-11-16 | 2001-12-13 | Peter Maccallum Cancer Institute, The | Method of enhancing self renewal of stem cells and uses thereof |
| US7592174B2 (en) | 2002-05-31 | 2009-09-22 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation of mesenchymal stem cells |
| RU2004138292A (ru) * | 2002-06-04 | 2005-06-10 | Галдерма Ресерч Энд Девелопмент, С.Н.С. (Fr) | Новые лиганды в качестве ингибиторов рецепторов rar, способы их получения и применение в медицине и косметике для человека |
| DE60326453D1 (de) * | 2002-07-03 | 2009-04-16 | Ct Cardiologico Monzino S P A | Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung |
| WO2004007697A2 (en) | 2002-07-16 | 2004-01-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of implanting mesenchymal stem cells for tissue repair and formation |
| US20050101581A1 (en) | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
| EP2418220B1 (en) | 2003-12-10 | 2017-08-02 | E. R. Squibb & Sons, L.L.C. | Interferon alpha antibodies and their uses |
| JP2005206544A (ja) * | 2004-01-23 | 2005-08-04 | Yasuyoshi Uchida | 筋肉再生剤 |
| AU2005240078A1 (en) * | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
| WO2005115304A2 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating fibrodysplasia |
| US7345931B2 (en) | 2005-08-01 | 2008-03-18 | Infineon Technologies Ag | Maintaining internal voltages of an integrated circuit in response to a clocked standby mode |
| FR2894959B1 (fr) | 2005-12-15 | 2008-02-29 | Galderma Res & Dev | Derives biphenyliques agonistes selectifs du recepteur rar-gamma |
| FR2894960B1 (fr) | 2005-12-15 | 2008-02-29 | Galderma Res & Dev | Derives biphenyliques agonistes selectifs du recepteurs rar-gamma |
| EP1999626A4 (en) | 2006-01-26 | 2009-11-25 | Combinatorx Inc | METHODS, COMPOSITIONS AND NEEDS FOR TREATING MUSCULOSKELETAL DISORDERS AND SYMPTOMS ASSOCIATED THEREWITH |
| ES2395401T3 (es) * | 2006-03-23 | 2013-02-12 | Tmrc Co., Ltd. | kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer |
| CN101410379B (zh) | 2006-03-31 | 2011-07-27 | 霍夫曼-拉罗奇有限公司 | 制备类维生素a类化合物的方法 |
| WO2007136653A2 (en) | 2006-05-16 | 2007-11-29 | Vitae Pharmaceuticals, Inc. | Use of a rar antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects |
| US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| EP2265603B1 (en) | 2008-03-13 | 2014-05-07 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| WO2010071583A1 (en) | 2008-12-18 | 2010-06-24 | Astrazeneca Ab | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient |
| EP2393915A4 (en) * | 2009-02-05 | 2012-12-26 | Regenertech Pty Ltd | PROCESS FOR THE PREPARATION OF PRECURSOR CELLS FROM DIFFERENTIATED CELLS |
| WO2011011513A1 (en) | 2009-07-21 | 2011-01-27 | University Of Washington Through Its Center For Commercialization | Inhibition of pathological bone formation |
| UA50725U (ru) * | 2009-12-01 | 2010-06-25 | Институт Нейрохирургии Им. Акад. А.П. Ромоданова Амн Украины | Способ лечения больных с прогрессирующей мышечной дистрофией трансплантацией миобластов эмбриона человека |
| CN103200937B (zh) | 2010-09-01 | 2020-07-03 | 托马斯杰弗逊大学 | 用于肌肉修复和再生的组合物和方法 |
| US10485780B2 (en) | 2011-03-14 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of proliferative disorders |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| EP2726084A1 (en) | 2011-07-01 | 2014-05-07 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Method of treating pathologic heterotopic ossification |
| BR112014020773A2 (pt) | 2012-02-22 | 2020-10-27 | Sanford-Burnham Medical Research Institute | compostos de sulfonamida e seus usos como inibidores tnap |
| CA2886187C (en) | 2012-09-28 | 2020-04-14 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
| EP2964651A4 (en) | 2013-03-04 | 2016-11-30 | Brigham & Womens Hospital | BMP HEMMER AND METHOD OF USE THEREOF |
| WO2014160203A2 (en) | 2013-03-14 | 2014-10-02 | The Brigham And Women's Hospital, Inc. | Bmp inhibitors and methods of use thereof |
| KR102303316B1 (ko) | 2013-05-22 | 2021-09-23 | 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 | 망막 맥락막 장해의 억제제 |
| JP2017536411A (ja) | 2014-10-01 | 2017-12-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | Ｂｍｐ阻害用組成物及びｂｍｐ阻害方法 |
| US20180311356A1 (en) | 2015-10-19 | 2018-11-01 | The Children's Medical Center Corporation | Method to inhibit endothelial-to-mesenchymal transition |
| JP6589119B2 (ja) | 2015-12-24 | 2019-10-16 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ | 異所性骨化を治療する方法 |
| CN120204216A (zh) | 2016-06-08 | 2025-06-27 | 同理制药公司 | 用于治疗异位骨化的方法 |
| JP6630255B2 (ja) | 2016-09-30 | 2020-01-15 | 株式会社沖データ | 画像形成装置及び通信システム |
-
2011
- 2011-08-31 CN CN201180052926.XA patent/CN103200937B/zh active Active
- 2011-08-31 CN CN202010493245.8A patent/CN111773213B/zh active Active
- 2011-08-31 EA EA201370051A patent/EA026251B1/ru unknown
- 2011-08-31 CA CA2809374A patent/CA2809374C/en active Active
- 2011-08-31 BR BR112013004685-6A patent/BR112013004685B1/pt active IP Right Grant
- 2011-08-31 DK DK11822537.4T patent/DK2613776T3/da active
- 2011-08-31 EP EP22154427.3A patent/EP4066826B1/en active Active
- 2011-08-31 ES ES11822537T patent/ES2823234T3/es active Active
- 2011-08-31 NZ NZ607547A patent/NZ607547A/en unknown
- 2011-08-31 EP EP11822537.4A patent/EP2613776B1/en active Active
- 2011-08-31 AU AU2011296080A patent/AU2011296080B2/en active Active
- 2011-08-31 PT PT118225374T patent/PT2613776T/pt unknown
- 2011-08-31 JP JP2013527250A patent/JP5986570B2/ja active Active
- 2011-08-31 ES ES22154427T patent/ES2975123T3/es active Active
- 2011-08-31 PL PL20171639T patent/PL3721880T3/pl unknown
- 2011-08-31 EP EP20171639.6A patent/EP3721880B1/en active Active
- 2011-08-31 MX MX2013002275A patent/MX361414B/es active IP Right Grant
- 2011-08-31 HU HUE20171639A patent/HUE059024T2/hu unknown
- 2011-08-31 WO PCT/US2011/049905 patent/WO2012030919A2/en not_active Ceased
- 2011-08-31 US US13/819,914 patent/US9789074B2/en active Active
- 2011-08-31 HU HUE11822537A patent/HUE051664T2/hu unknown
- 2011-08-31 DK DK20171639.6T patent/DK3721880T3/da active
- 2011-08-31 PL PL11822537T patent/PL2613776T3/pl unknown
- 2011-08-31 ES ES20171639T patent/ES2912593T3/es active Active
-
2013
- 2013-02-26 MX MX2018015032A patent/MX2018015032A/es unknown
- 2013-02-28 CL CL2013000580A patent/CL2013000580A1/es unknown
- 2013-02-28 IL IL224973A patent/IL224973B/en active IP Right Grant
- 2013-02-28 ZA ZA2013/01536A patent/ZA201301536B/en unknown
- 2013-03-05 CO CO13044010A patent/CO6680694A2/es not_active Application Discontinuation
-
2014
- 2014-06-18 US US14/308,570 patent/US9314439B2/en active Active
-
2017
- 2017-08-10 US US15/674,357 patent/US10292954B2/en active Active
-
2019
- 2019-04-09 US US16/379,178 patent/US11433039B2/en active Active
-
2022
- 2022-08-04 US US17/881,207 patent/US12023312B2/en active Active
-
2024
- 2024-05-06 US US18/655,854 patent/US20250108022A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013536855A5 (enExample) | ||
| JP2005522476A5 (enExample) | ||
| JP2012502957A5 (enExample) | ||
| Orfanos et al. | Oral retinoids in the treatment of seborrhoea and acne | |
| JP2009528296A5 (enExample) | ||
| NZ607547A (en) | Composition and method for muscle repair and regeneration | |
| JP2008530101A5 (enExample) | ||
| JP5172911B2 (ja) | 癒着の予防及び／又は治療のための医薬 | |
| PT637297E (pt) | Compostos com selectividade para os receptores de retinoide x | |
| RU2017129434A (ru) | Амидные производные n-карбамид-замещенных аминокислот как модуляторы формилпептидного рецептора-1 (fprl-1) | |
| DK1507558T3 (da) | Farmaceutisk sammensætning omfattende en renininhibitor, en calciumkanalblokker og et diuretikum | |
| JP2014062126A5 (enExample) | ||
| JP2011507956A5 (enExample) | ||
| AU2010320911B2 (en) | Combination of alpha- 2 adrenergic receptor agonist and non-steroidal anti - inflammatory agent for treating or preventing an inflammatory skin disorder | |
| JP2006503809A5 (enExample) | ||
| Hoxha | Duchenne muscular dystrophy: Focus on arachidonic acid metabolites | |
| JP2016508141A5 (enExample) | ||
| JP2008537547A5 (enExample) | ||
| JP2005507381A5 (enExample) | ||
| JP5685364B2 (ja) | トリアゾール化合物による炎症性疾患の処置 | |
| JP2005517649A5 (enExample) | ||
| RU2009127747A (ru) | Применение непафенака или его производных для лечения дерматологических расстройств, связанных с нарушением кератинизации, которое может иметь иммуно-аллергическую воспалительную составляющую | |
| JP2003508515A5 (enExample) | ||
| JP2016535096A5 (enExample) | ||
| JPWO2024090521A5 (enExample) |